BH3 Stock Overview
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
PTC Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$26.40 |
52 Week High | US$54.50 |
52 Week Low | US$16.40 |
Beta | 0.66 |
1 Month Change | 11.86% |
3 Month Change | 3.94% |
1 Year Change | -37.14% |
3 Year Change | -34.65% |
5 Year Change | -21.87% |
Change since IPO | 97.41% |
Recent News & Updates
Recent updates
Shareholder Returns
BH3 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0.8% | 2.1% | 1.9% |
1Y | -37.1% | 37.0% | 7.3% |
Return vs Industry: BH3 underperformed the German Biotechs industry which returned 35.8% over the past year.
Return vs Market: BH3 underperformed the German Market which returned 6.4% over the past year.
Price Volatility
BH3 volatility | |
---|---|
BH3 Average Weekly Movement | 9.9% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BH3 has not had significant price volatility in the past 3 months.
Volatility Over Time: BH3's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 1,022 | Matt Klein | https://www.ptcbio.com |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis.
PTC Therapeutics, Inc. Fundamentals Summary
BH3 fundamental statistics | |
---|---|
Market cap | €2.04b |
Earnings (TTM) | -€578.54m |
Revenue (TTM) | €865.89m |
2.3x
P/S Ratio-3.4x
P/E RatioIs BH3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BH3 income statement (TTM) | |
---|---|
Revenue | US$937.82m |
Cost of Revenue | US$732.05m |
Gross Profit | US$205.77m |
Other Expenses | US$832.38m |
Earnings | -US$626.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -8.18 |
Gross Margin | 21.94% |
Net Profit Margin | -66.81% |
Debt/Equity Ratio | -256.3% |
How did BH3 perform over the long term?
See historical performance and comparison